Skip to content

Effect of Anahil Tablets on Cesarean Section Scar

Evaluation of the Effect of Bromelain Supplementation Named Anahil Tablets on Cesarean Section Scar: A Randomized Double-Blind Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251015067639N1
Enrollment
90
Registered
2025-11-01
Start date
2025-11-20
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section. Encounter for cesarean delivery without indication

Interventions

Intervention 1: Intervention group: After cesarean section, each member of the intervention group will receive a can containing 22 Anahil 500 mg tablets from Salamat Permon Amin Company, Tehran-Iran,

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: No use of dexamethasone during and after surgery No vascular disease No coagulation disorders No history of sensitivity to bromelain and any pineapple derivatives No hypertension, diabetes, rheumatic diseases, kidney failure, or liver disease No use of anti-inflammatory drugs, steroids, corticosteroids, tetracycline, or amoxicillin Horizontal cesarean section Consent to participate in the study

Exclusion criteria

Exclusion criteria: Withdrawal from the study Severe side effects due to supplement use Failure of the patient to adhere to the treatment protocol Loss to follow-up

Design outcomes

Primary

MeasureTime frame
Total scar quality score based on the Vancouver Scar Scale (VSS). Timepoint: Days 1, 7, and 11 after surgery. Method of measurement: Pain: NRS scale (0-10) will be used.Edema: Edema Grading Scale (+1-+4) will be used to measure the degree of edema at the scar site.Redness and skin discoloration: Erythema Grading Scale (1-4) will be used to measure the severity of redness and skin discoloration.Infection: The degree of infection will be measured through clinical criteria such as the presence of pus, odor, etc.Disintegration: SWD scale with 4 grades will be used to measure the degree of disruption at the scar site.

Secondary

MeasureTime frame
Pain intensity at the incision site — measured using the Visual Analogue Scale (VAS) at baseline, week 1, and week 4 after cesarean section.Incision site inflammation score — evaluated clinically at week 1 and week 4 post-operation.Incidence of wound infection — defined by redness, discharge, or positive culture findings within 4 weeks following surgery.Patient satisfaction with cosmetic appearance of the scar — assessed using a 5-point Likert scale at week 4.Analgesic consumption (e.g., acetaminophen use) — recorded throughout the 4-week postoperative period. Timepoint: Days 1, 7, and 11 after surgery. Method of measurement: Pain: NRS scale (0-10) will be used.Edema: Edema Grading Scale (+1-+4) will be used to measure the degree of edema at the scar site.Redness and skin discoloration: Erythema Grading Scale (1-4) will be used to measure the severity of redness and skin discoloration.Infection: The degree of infection will be measured through clinical criteria such as the presence of pus, odor, etc.Disintegration: SWD scale with 4 grades will be used to measure the degree of disruption at the scar site.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Seydi Aqilabadi

Arak University of Medical Sciences

f.seydi1600@gmail.com+98 990 375 8996

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026